Shopping Cart 0
Cart Subtotal
USD 0

J Uriach Y Compania SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

J Uriach Y Compania SA (Uriach) is a pharmaceutical company that offers food supplements, cosmetics and OTC products. It also researches, develops and manufactures active ingredients for the pharmaceutical market. Uriach provides antiflatulents, antifungals, mineral supplements and antiplatelet drugs among others. The company offers its products in the form of tablets, powders, capsules, pills, granules, creams and ointments. It also provides contract manufacturing services. Uriach spans its expertise in the development and marketing of generic files for international licensing. It offers products for sleep and relaxation, skin and beauty, energy and sport, irritation and wounds and others. Uriach is headquartered at Barcelona, Spain.

J Uriach Y Compania SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

J Uriach Y Compania SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 10

Licensing Agreements 11

Uriach Enters into Licensing Agreement with Teikoku Seiyaku for Rupatadine 11

Ahn-Gook Pharm Enters Into Licensing Agreement With Grupo Uriach For Rhinitis Drug 12

Asset Transactions 13

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 13

Palau Pharma Sells UR-65318 To US Pharma Company 14

Draconis Pharma Acquires Drug Discovery Unit Of Palau Pharma 15

Acquisition 16

Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 16

J Uriach Y Compania SA-Key Competitors 18

Key Employees 19

Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Financial Announcements 21

May 11, 2016: Uriach grows by 10% in 2015, reinforcing its status as a reference for financial performance in the pharmaceutical sector 21

Appendix 22

Methodology 22

About GlobalData 22

Contact Us 22

Disclaimer 22


List Of Figure

List of Figures

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Key Facts 1

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

J Uriach Y Compania SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

J Uriach Y Compania SA, Deals By Therapy Area, 2011 to YTD 2017 8

J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 10

Uriach Enters into Licensing Agreement with Teikoku Seiyaku for Rupatadine 11

Ahn-Gook Pharm Enters Into Licensing Agreement With Grupo Uriach For Rhinitis Drug 12

Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 13

Palau Pharma Sells UR-65318 To US Pharma Company 14

Draconis Pharma Acquires Drug Discovery Unit Of Palau Pharma 15

Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 16

J Uriach Y Compania SA, Key Competitors 18

J Uriach Y Compania SA, Key Employees 19

J Uriach Y Compania SA, Other Locations 20

J Uriach Y Compania SA, Subsidiaries 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

J Uriach Y Compania SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.